CLINICAL MANIFESTATIONS OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES ASSOCIATED VASCULITIS

Autori:

Jadranka Morović-Vergles, Melanie-Ivana Čulo, Anamarija Sutić

Sažetak

ANCA vaskulitisi su rijetke bolesti, koje se u prosjeku javljaju u 30 na milijun stanovnika. Riječ je o sistemskim nekrotizirajućim vaskulitisima (histološki se nalazi nekroza medije uz upalu intime i adventicije), a u pojedinim ANCA vaskulitisima granulomi okružuju krvne žile. U skupinu ANCA vaskulitisa ubrajaju se poliangiitis s granulomatozom (GPA), nekad nazivan Wegenerovom granulomatozom, mikroskopski poliangiitis (MPA) i poliangiitis s eozinofilnim granulomima (EGPA), prije poznat kao Churg-Straussov vaskulitis. Prema novoj nomenklaturi eponimi se zamjenjuju odgovarajućim opisnim nazivima za pojedine entitete. ANCA vaskulitisi čine zasebnu skupinu vaskulitisa s obzirom na to da najčešće zahvaćaju malene, katkad i srednje velike krvne žile, obično su udruženi s ANCA protutijelima i povezani s visokim rizikom od nastanka glomerulonefritisa te dobrim odgovorom na imunosupresivno liječenje ciklofosfamidom.

Summary

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides are rare diseases, with the average of 30 new cases per million inhabitants per year. Their main characteristic is systemic involvement with necrosis of the vessel walls (histological changes showing necrosis of the media and inflammation of adventitia and intima). In some forms granulomas may be found surrounding the vessels. ANCA-associated vasculitides include granulomatosis with polyangiitis (GPA, previously called Wegener’s), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA, previously called Churg-Straus). Honorific eponyms are now changing to a disease-descriptive or etiology-based nomenclature. ANCA-associated vasculitides are a distinctive group of vasculitides because they dominantly involve small sized vessels, sometimes even medium sized vessels, are associated with antineutrophil cytoplasmic antibodies with high risk of developing glomerulonephritis and respond well to immunosuppresion with cyclophosphamide.

Volumen: 7-8, 2014

Liječ Vjesn 2014;136:226–229

Preuzmi PDF